Close Menu

NEW YORK (GenomeWeb) – Rosetta Genomics today said that it plans to redirect "substantially all of our sales and marketing resources" to promote is RosettaGx Reveal test, following a preliminary 54 percent quarter over quarter growth in sales of the microRNA-based assay for classifying indeterminate thyroid nodules.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.